Jonathan Violin, Ph.D. is a venture partner at Fairmount Funds and previously served as interim chief executive officer of Crescent from October 2024 to March 2025. Prior to that, Dr. Violin served as president and chief operating officer, and later chief executive officer, of Viridian Therapeutics (formerly Miragen Therapeutics). Dr. Violin also co-founded Quellis Biosciences, which was acquired by Catabasis Pharmaceuticals in 2021, as well as Dianthus Therapeutics. He also served in various roles at Trevana, as well as holding various consultancy roles to life science companies throughout his career. Dr. Violin earned a Ph.D. in pharmacology from the University of California, San Diego. He also earned an MBA with a concentration in health sector management and a BS in chemical pharmacology from Duke University.